

Myelodysplastic Syndrome (MDS) Therapeutics Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/M1364E9B9A52EN.html>

Date: March 2022

Pages: 62

Price: US\$ 3,250.00 (Single User License)

ID: M1364E9B9A52EN

Abstracts

This report contains market size and forecasts of Myelodysplastic Syndrome (MDS) Therapeutics in Global, including the following market information:

Global Myelodysplastic Syndrome (MDS) Therapeutics Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Myelodysplastic Syndrome (MDS) Therapeutics market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Azacitidine Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Myelodysplastic Syndrome (MDS) Therapeutics include Novartis AG, Celgene Corporation, Otsuka Pharmaceutical Co., Ltd., Sandoz Inc., Dr Reddys Laboratories Limited, Pharmascience Inc., Accord Healthcare Ltd and Mylan N.V., etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Myelodysplastic Syndrome (MDS) Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry

trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Myelodysplastic Syndrome (MDS) Therapeutics Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Myelodysplastic Syndrome (MDS) Therapeutics Market Segment Percentages, by Type, 2021 (%)

Azacitidine

Lenalidomide

Decitabine

Deferasirox

Others

Global Myelodysplastic Syndrome (MDS) Therapeutics Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Myelodysplastic Syndrome (MDS) Therapeutics Market Segment Percentages, by Application, 2021 (%)

In-Patient

Out-Patient

Global Myelodysplastic Syndrome (MDS) Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Myelodysplastic Syndrome (MDS) Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Myelodysplastic Syndrome (MDS) Therapeutics revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Myelodysplastic Syndrome (MDS) Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Novartis AG

Celgene Corporation

Otsuka Pharmaceutical Co., Ltd.

Sandoz Inc.

Dr Reddys Laboratories Limited

Pharmascience Inc.

Accord Healthcare Ltd

Mylan N.V.

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Myelodysplastic Syndrome (MDS) Therapeutics Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL MYELODYSPLASTIC SYNDROME (MDS) THERAPEUTICS OVERALL MARKET SIZE

- 2.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size: 2021 VS 2028
- 2.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Myelodysplastic Syndrome (MDS) Therapeutics Players in Global Market
- 3.2 Top Global Myelodysplastic Syndrome (MDS) Therapeutics Companies Ranked by Revenue
- 3.3 Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue by Companies
- 3.4 Top 3 and Top 5 Myelodysplastic Syndrome (MDS) Therapeutics Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Myelodysplastic Syndrome (MDS) Therapeutics Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Myelodysplastic Syndrome (MDS) Therapeutics Players in Global Market
 - 3.6.1 List of Global Tier 1 Myelodysplastic Syndrome (MDS) Therapeutics Companies

3.6.2 List of Global Tier 2 and Tier 3 Myelodysplastic Syndrome (MDS) Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size Markets, 2021 & 2028

4.1.2 Azacitidine

4.1.3 Lenalidomide

4.1.4 Decitabine

4.1.5 Deferasirox

4.1.6 Others

4.2 By Type - Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue & Forecasts

4.2.1 By Type - Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue, 2017-2022

4.2.2 By Type - Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue, 2023-2028

4.2.3 By Type - Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size, 2021 & 2028

5.1.2 In-Patient

5.1.3 Out-Patient

5.2 By Application - Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue & Forecasts

5.2.1 By Application - Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue, 2017-2022

5.2.2 By Application - Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue, 2023-2028

5.2.3 By Application - Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size, 2021 & 2028

6.2 By Region - Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue & Forecasts

6.2.1 By Region - Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue, 2017-2022

6.2.2 By Region - Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue, 2023-2028

6.2.3 By Region - Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Myelodysplastic Syndrome (MDS) Therapeutics Revenue, 2017-2028

6.3.2 US Myelodysplastic Syndrome (MDS) Therapeutics Market Size, 2017-2028

6.3.3 Canada Myelodysplastic Syndrome (MDS) Therapeutics Market Size, 2017-2028

6.3.4 Mexico Myelodysplastic Syndrome (MDS) Therapeutics Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Myelodysplastic Syndrome (MDS) Therapeutics Revenue, 2017-2028

6.4.2 Germany Myelodysplastic Syndrome (MDS) Therapeutics Market Size, 2017-2028

6.4.3 France Myelodysplastic Syndrome (MDS) Therapeutics Market Size, 2017-2028

6.4.4 U.K. Myelodysplastic Syndrome (MDS) Therapeutics Market Size, 2017-2028

6.4.5 Italy Myelodysplastic Syndrome (MDS) Therapeutics Market Size, 2017-2028

6.4.6 Russia Myelodysplastic Syndrome (MDS) Therapeutics Market Size, 2017-2028

6.4.7 Nordic Countries Myelodysplastic Syndrome (MDS) Therapeutics Market Size, 2017-2028

6.4.8 Benelux Myelodysplastic Syndrome (MDS) Therapeutics Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Myelodysplastic Syndrome (MDS) Therapeutics Revenue, 2017-2028

6.5.2 China Myelodysplastic Syndrome (MDS) Therapeutics Market Size, 2017-2028

6.5.3 Japan Myelodysplastic Syndrome (MDS) Therapeutics Market Size, 2017-2028

6.5.4 South Korea Myelodysplastic Syndrome (MDS) Therapeutics Market Size, 2017-2028

6.5.5 Southeast Asia Myelodysplastic Syndrome (MDS) Therapeutics Market Size, 2017-2028

6.5.6 India Myelodysplastic Syndrome (MDS) Therapeutics Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Myelodysplastic Syndrome (MDS) Therapeutics Revenue, 2017-2028

6.6.2 Brazil Myelodysplastic Syndrome (MDS) Therapeutics Market Size, 2017-2028

6.6.3 Argentina Myelodysplastic Syndrome (MDS) Therapeutics Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Revenue, 2017-2028

6.7.2 Turkey Myelodysplastic Syndrome (MDS) Therapeutics Market Size, 2017-2028

6.7.3 Israel Myelodysplastic Syndrome (MDS) Therapeutics Market Size, 2017-2028

6.7.4 Saudi Arabia Myelodysplastic Syndrome (MDS) Therapeutics Market Size, 2017-2028

6.7.5 UAE Myelodysplastic Syndrome (MDS) Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Novartis AG

7.1.1 Novartis AG Corporate Summary

7.1.2 Novartis AG Business Overview

7.1.3 Novartis AG Myelodysplastic Syndrome (MDS) Therapeutics Major Product Offerings

7.1.4 Novartis AG Myelodysplastic Syndrome (MDS) Therapeutics Revenue in Global Market (2017-2022)

7.1.5 Novartis AG Key News

7.2 Celgene Corporation

7.2.1 Celgene Corporation Corporate Summary

7.2.2 Celgene Corporation Business Overview

7.2.3 Celgene Corporation Myelodysplastic Syndrome (MDS) Therapeutics Major Product Offerings

7.2.4 Celgene Corporation Myelodysplastic Syndrome (MDS) Therapeutics Revenue in Global Market (2017-2022)

7.2.5 Celgene Corporation Key News

7.3 Otsuka Pharmaceutical Co., Ltd.

7.3.1 Otsuka Pharmaceutical Co., Ltd. Corporate Summary

7.3.2 Otsuka Pharmaceutical Co., Ltd. Business Overview

7.3.3 Otsuka Pharmaceutical Co., Ltd. Myelodysplastic Syndrome (MDS) Therapeutics Major Product Offerings

7.3.4 Otsuka Pharmaceutical Co., Ltd. Myelodysplastic Syndrome (MDS) Therapeutics

Revenue in Global Market (2017-2022)

7.3.5 Otsuka Pharmaceutical Co., Ltd. Key News

7.4 Sandoz Inc.

7.4.1 Sandoz Inc. Corporate Summary

7.4.2 Sandoz Inc. Business Overview

7.4.3 Sandoz Inc. Myelodysplastic Syndrome (MDS) Therapeutics Major Product Offerings

7.4.4 Sandoz Inc. Myelodysplastic Syndrome (MDS) Therapeutics Revenue in Global Market (2017-2022)

7.4.5 Sandoz Inc. Key News

7.5 Dr Reddys Laboratories Limited

7.5.1 Dr Reddys Laboratories Limited Corporate Summary

7.5.2 Dr Reddys Laboratories Limited Business Overview

7.5.3 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Therapeutics Major Product Offerings

7.5.4 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Therapeutics Revenue in Global Market (2017-2022)

7.5.5 Dr Reddys Laboratories Limited Key News

7.6 Pharmascience Inc.

7.6.1 Pharmascience Inc. Corporate Summary

7.6.2 Pharmascience Inc. Business Overview

7.6.3 Pharmascience Inc. Myelodysplastic Syndrome (MDS) Therapeutics Major Product Offerings

7.6.4 Pharmascience Inc. Myelodysplastic Syndrome (MDS) Therapeutics Revenue in Global Market (2017-2022)

7.6.5 Pharmascience Inc. Key News

7.7 Accord Healthcare Ltd

7.7.1 Accord Healthcare Ltd Corporate Summary

7.7.2 Accord Healthcare Ltd Business Overview

7.7.3 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Therapeutics Major Product Offerings

7.7.4 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Therapeutics Revenue in Global Market (2017-2022)

7.7.5 Accord Healthcare Ltd Key News

7.8 Mylan N.V.

7.8.1 Mylan N.V. Corporate Summary

7.8.2 Mylan N.V. Business Overview

7.8.3 Mylan N.V. Myelodysplastic Syndrome (MDS) Therapeutics Major Product Offerings

7.8.4 Mylan N.V. Myelodysplastic Syndrome (MDS) Therapeutics Revenue in Global Market (2017-2022)

7.8.5 Mylan N.V. Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Myelodysplastic Syndrome (MDS) Therapeutics Market Opportunities & Trends in Global Market

Table 2. Myelodysplastic Syndrome (MDS) Therapeutics Market Drivers in Global Market

Table 3. Myelodysplastic Syndrome (MDS) Therapeutics Market Restraints in Global Market

Table 4. Key Players of Myelodysplastic Syndrome (MDS) Therapeutics in Global Market

Table 5. Top Myelodysplastic Syndrome (MDS) Therapeutics Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Share by Companies, 2017-2022

Table 8. Global Companies Myelodysplastic Syndrome (MDS) Therapeutics Product Type

Table 9. List of Global Tier 1 Myelodysplastic Syndrome (MDS) Therapeutics Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Myelodysplastic Syndrome (MDS) Therapeutics Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Myelodysplastic Syndrome (MDS) Therapeutics Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Myelodysplastic Syndrome (MDS) Therapeutics Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Myelodysplastic Syndrome (MDS) Therapeutics Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Myelodysplastic Syndrome (MDS) Therapeutics Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue

(US\$, Mn), 2017-2022

Table 19. By Region - Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 30. Novartis AG Corporate Summary

Table 31. Novartis AG Myelodysplastic Syndrome (MDS) Therapeutics Product Offerings

Table 32. Novartis AG Myelodysplastic Syndrome (MDS) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 33. Celgene Corporation Corporate Summary

Table 34. Celgene Corporation Myelodysplastic Syndrome (MDS) Therapeutics Product Offerings

Table 35. Celgene Corporation Myelodysplastic Syndrome (MDS) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 36. Otsuka Pharmaceutical Co., Ltd. Corporate Summary

Table 37. Otsuka Pharmaceutical Co., Ltd. Myelodysplastic Syndrome (MDS) Therapeutics Product Offerings

Table 38. Otsuka Pharmaceutical Co., Ltd. Myelodysplastic Syndrome (MDS) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 39. Sandoz Inc. Corporate Summary

Table 40. Sandoz Inc. Myelodysplastic Syndrome (MDS) Therapeutics Product Offerings

Table 41. Sandoz Inc. Myelodysplastic Syndrome (MDS) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 42. Dr Reddys Laboratories Limited Corporate Summary

Table 43. Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Therapeutics Product Offerings

Table 44. Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 45. Pharmascience Inc. Corporate Summary

Table 46. Pharmascience Inc. Myelodysplastic Syndrome (MDS) Therapeutics Product Offerings

Table 47. Pharmascience Inc. Myelodysplastic Syndrome (MDS) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 48. Accord Healthcare Ltd Corporate Summary

Table 49. Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Therapeutics Product Offerings

Table 50. Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 51. Mylan N.V. Corporate Summary

Table 52. Mylan N.V. Myelodysplastic Syndrome (MDS) Therapeutics Product Offerings

Table 53. Mylan N.V. Myelodysplastic Syndrome (MDS) Therapeutics Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Myelodysplastic Syndrome (MDS) Therapeutics Segment by Type in 2021

Figure 2. Myelodysplastic Syndrome (MDS) Therapeutics Segment by Application in 2021

Figure 3. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue, 2017-2028 (US\$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by Myelodysplastic Syndrome (MDS) Therapeutics Revenue in 2021

Figure 8. By Type - Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share, 2017-2028

Figure 9. By Application - Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share, 2017-2028

Figure 10. By Region - Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share, 2017-2028

Figure 11. By Country - North America Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share, 2017-2028

Figure 12. US Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 13. Canada Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 14. Mexico Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 15. By Country - Europe Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share, 2017-2028

Figure 16. Germany Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 17. France Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 18. U.K. Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 19. Italy Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn),

2017-2028

Figure 20. Russia Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share, 2017-2028

Figure 24. China Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 28. India Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share, 2017-2028

Figure 30. Brazil Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share, 2017-2028

Figure 33. Turkey Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Myelodysplastic Syndrome (MDS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 37. Novartis AG Myelodysplastic Syndrome (MDS) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Celgene Corporation Myelodysplastic Syndrome (MDS) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Otsuka Pharmaceutical Co., Ltd. Myelodysplastic Syndrome (MDS) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Sandoz Inc. Myelodysplastic Syndrome (MDS) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Pharmascience Inc. Myelodysplastic Syndrome (MDS) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Mylan N.V. Myelodysplastic Syndrome (MDS) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Myelodysplastic Syndrome (MDS) Therapeutics Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/M1364E9B9A52EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M1364E9B9A52EN.html>